Intensity Therapeutics Reports INT230-6 Can Cause Immune Priming in Historically Quiescent Breast Cancers : vimarsana.com

/PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity"), a clinical-stage biotechnology company focused on the discovery and development of proprietary,...

Related Keywords

Canada , Chicago , Illinois , United States , Ottawa , Ontario , Westport , American , Edna Kaplan , Bristol Myers Squibb , Lewish Bender , Merck Sharpe Dohme , Michael Miller , Angel Arnaout , Approval Program , American Society Of Clinical Oncology , Vaccine Branch , Development Agreement , University Of Ottawa , National Cancer Institute , Health Canada , Ontario Institute For Cancer Research , Company On Twitter , Rx Communications Group , Intensity Therapeutics Inc , Drug Administration , Ottawa Hospital Research Institute , T Cell Receptor Signaling , Macrophage Markers , B Cell Receptor , Was Presented , Clinical Oncology , Annual Meeting , Intensity Therapeutics , Breast Cancer , Surgical Oncologist , Ottawa Hospital , Ontario Institute , Cancer Research , Melanie Spears , Diagnostic Development , Chief Executive Officer , Clinical Trial Application , Principal Investigator , Accelerated Approval Program , Merck Sharpe , Cooperative Research , Intensity Therapeutic , Relations Contact , Nc ,